667 related articles for article (PubMed ID: 19354072)
1. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study.
Serrano P; Justicia JL; Sánchez C; Cimarra M; Fernández-Távora L; Orovitg A; Moreno C; Guerra F; Alvà V
Ann Allergy Asthma Immunol; 2009 Mar; 102(3):247-52. PubMed ID: 19354072
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of adverse reactions induced by subcutaneous immunotherapy against dust mite allergy in 234 cases with allergic rhinitis and asthma].
Li MR; Wang XN; Jiang HD; Wang QY; Li YC; Lin J; Jin K; Zhang HL; Li CC
Zhonghua Er Ke Za Zhi; 2012 Oct; 50(10):726-31. PubMed ID: 23302557
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability and efficacy of sublingual allergoid immunotherapy with a 4-day shortened build-up phase.
Giordano T; Quarta C; Bruno ME; Falagiani P; Riva G
Eur Ann Allergy Clin Immunol; 2006 Nov; 38(9):310-2. PubMed ID: 17191751
[TBL] [Abstract][Full Text] [Related]
4. Is faster safer? Cluster versus short conventional subcutaneous allergen immunotherapy.
Quiralte J; Justicia JL; Cardona V; Dávila I; Moreno E; Ruiz B; García MA
Immunotherapy; 2013 Dec; 5(12):1295-303. PubMed ID: 24283840
[TBL] [Abstract][Full Text] [Related]
5. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
[TBL] [Abstract][Full Text] [Related]
6. The safety of allergen immunotherapy (IT) in Turkey.
Dursun AB; Sin BA; Oner F; Misirligil Z
J Investig Allergol Clin Immunol; 2006; 16(2):123-8. PubMed ID: 16689186
[TBL] [Abstract][Full Text] [Related]
7. Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results.
Esch RE; Bush RK; Peden D; Lockey RF
Ann Allergy Asthma Immunol; 2008 May; 100(5):475-81. PubMed ID: 18517081
[TBL] [Abstract][Full Text] [Related]
8. Comparative study of cluster and conventional immunotherapy schedules with dermatophagoides pteronyssinus in the treatment of persistent allergic rhinitis.
Zhang L; Wang C; Han D; Wang X; Zhao Y; Liu J
Int Arch Allergy Immunol; 2009; 148(2):161-9. PubMed ID: 18802361
[TBL] [Abstract][Full Text] [Related]
9. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
[TBL] [Abstract][Full Text] [Related]
10. Accelerated up-dosing of subcutaneous immunotherapy with a registered allergoid grass pollen preparation.
Pfaar O; van Twuijver E; Hecker H; Boot JD; van Ree R; Klimek L
Int Arch Allergy Immunol; 2013; 160(4):420-4. PubMed ID: 23183541
[TBL] [Abstract][Full Text] [Related]
11. High-dose sublingual immunotherapy in children at 8-year follow-up.
Leonardi S; Spicuzza L; La Rosa M
Ann Allergy Asthma Immunol; 2009 Mar; 102(3):259-60. PubMed ID: 19354077
[No Abstract] [Full Text] [Related]
12. [Vaccination with allergens in children].
Demoly P; Dhivert-Donnadieu H; Bousquet J
Allerg Immunol (Paris); 2000 Dec; 32(10):397-401. PubMed ID: 11209473
[TBL] [Abstract][Full Text] [Related]
13. Safety of an ultra-rush immunotherapy build-up schedule with therapeutic vaccines containing depigmented and polymerized allergen extracts.
Casanovas M; Martín R; Jiménez C; Caballero R; Fernández-Caldas E
Int Arch Allergy Immunol; 2006; 139(2):153-8. PubMed ID: 16374026
[TBL] [Abstract][Full Text] [Related]
14. Nonfatal systemic reactions to subcutaneous immunotherapy: a 10-year experience.
Ragusa FV; Passalacqua G; Gambardella R; Campanari S; Barbieri MM; Scordamaglia A; Canonica GW
J Investig Allergol Clin Immunol; 1997; 7(3):151-4. PubMed ID: 9252872
[TBL] [Abstract][Full Text] [Related]
15. The local and systemic side-effects of venom and inhaled-allergen subcutaneous immunotherapy.
Adamic K; Zidarn M; Bajrovic N; Erzen R; Kopac P; Music E
Wien Klin Wochenschr; 2009; 121(9-10):357-60. PubMed ID: 19562302
[TBL] [Abstract][Full Text] [Related]
16. Safety of sublingual grass pollen immunotherapy after anaphylaxis.
Nichani JR; de Carpentier J
J Laryngol Otol; 2009 Jun; 123(6):683-4. PubMed ID: 18501039
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of specific immunotherapy with standardized allergenic extracts adsorbed on aluminium hydroxide.
Wüthrich B; Gumowski PL; Fäh J; Hürlimann A; Deluze C; André C; Fadel R; Carat F
J Investig Allergol Clin Immunol; 2001; 11(3):149-56. PubMed ID: 11831445
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy.
Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D
Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368
[TBL] [Abstract][Full Text] [Related]
19. [Sublingual immunotherapy in children with grass pollen induced allergic rhinoconjunctivitis].
Wolthers OD; Høst A; Frederiksen B; Halken S
Ugeskr Laeger; 2012 Aug; 174(35):1989-92. PubMed ID: 22929576
[TBL] [Abstract][Full Text] [Related]
20. Accelerated Up-Dosing of Subcutaneous Immunotherapy with a Registered Allergoid Birch Pollen Preparation.
Buczyłko K; van der Werf JF; Boot D; van Ree R
Int Arch Allergy Immunol; 2017; 172(3):183-186. PubMed ID: 28380494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
